Osteoarthritis Treatment to 2024: Global Market to be Dominated by Non-steroidal Anti-inflammatory Drugs (NSAIDs)
DUBLIN, March 15, 2019 /PRNewswire/ -- The "Osteoarthritis Treatment Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
The osteoarthritis treatment market is expected to register a CAGR of nearly 4.2% during the forecast period, 2019-2024.
The growth of the global osteoarthritis treatment market is due to the rising geriatric population, increasing incidence of osteoarthritis disorders, and rising demand for minimally invasive surgical procedures.
The global increase in geriatric population leads to higher incidence of osteoarthritis (OA) among the aged population. It is the most common type of joint disease, found in people aged more than 65 years, which is accompanied by mortality and decreased quality of life. Osteoarthritis (OA) is one of the most common causes of pain and disability in the elderly population and is driving the growth of the market.
There has also been a rising demand for minimally invasive surgical procedures to treat osteoarthritis, worldwide. MAKOplasty is a minimally invasive knee surgery that relieves the pain caused by osteoarthritis. However, there are also various minimally invasive surgeries that have been reported and are being used nowadays, as they cause less pain and incisions.
In addition, there are many osteoarthritis research studies ongoing on cartilage, the lubricating surface in the joint. The work is being done to re-grow the cartilage using stem cells treated with molecules to aid their growth. Hence, ongoing research and rising government support help in creating new opportunities for the growth of the osteoarthritis treatment market.
Key Market Trends
Non-steroidal Anti-inflammatory Drugs (NSAIDs) is the Largest Segment Under Drugs that is Expected to Grow During the Forecast Period
The NSAIDs market is expected to grow during the forecast period, as they are found to be the most commonly used drugs to ease pain, inflammation, and stiffness that come with arthritis, bursitis, and tendinitis. Thus, NSAIDs have been an important treatment for the symptoms of osteoarthritis for a very long time. They are also cheap and often among the first medicines prescribed for people with achy joints.
The hyaluronic acid injections are also used as a treatment option, when a patient is no longer able to control osteoarthritis pain with ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs).
North America has been reported with the Fastest and the Largest Growth and is Expected to follow the Same Trend over the Forecast Period
The North American market is expected to grow, owing to the increasing lifestyle changes, an increasing number of obesity cases, and an extensive rise in the geriatric population in North America. As a result, the adoption of treatment and drugs is also increasing in the region. The availability of better treatment options, high awareness among people, government reimbursement policies, and the willingness to take up treatment are expected to add up to the growth of the osteoarthritis treatment market in the region.
Various manufacturers are expanding, owing to new product launches in the market. These manufacturers have also seen positive developments in the United States, Europe, Latin America, and Asia. There are also strict regulatory policies, which have resulted in a reduction of investments made by the drug companies in the R&D of new products.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Increasing Incidence of Orthopedic Disorders
4.2.3 Rising Demand for Minimally Invasive Surgical Procedures
4.3 Market Restraints
4.3.1 High Cost Associated with Hyaluronic Acid Products
4.3.2 High Side Effects and Lack of Safety of Products
4.4 Porter's Five Forces Analysis
5 Market Segmentation
5.1 By Drugs
5.1.1 By Food Supplements
188.8.131.52 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
184.108.40.206 Hyaluronic Acid Injection
220.127.116.11.1 Single Injections
18.104.22.168.2 Multiple Injections
22.214.171.124 Other Drugs
5.1.2 By Anatomy
126.96.36.199 Ankle Osteoarthritis
188.8.131.52 Hip Osteoarthritis
184.108.40.206 Knee Osteoarthritis
220.127.116.11 Shoulder Osteoarthritis
18.104.22.168 Other Anatomies
5.2.1 North America
5.2.4 Middle East & Africa
5.2.5 South America
6 Competitive Landscape
6.1 Company Profiles
6.1.1 Bayer Healthcare
6.1.2 Lifecore Biomedical LLC
6.1.3 Merck Serono
6.1.4 Pfizer Consumer Healthcare
6.1.5 Iroko Pharmaceuticals
6.1.6 Sanofi S.A.
6.1.7 Smith & Nephew PLC
6.1.8 Zimmer Biomet
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/research/5jgr8z/osteoarthritis?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/osteoarthritis-treatment-to-2024-global-market-to-be-dominated-by-non-steroidal-anti-inflammatory-drugs-nsaids-300813241.html
SOURCE Research and Markets